MYC and Metastasis

Anita Wolfer1,2 and Sridhar Ramaswamy1–4

Abstract

Aggressive primary tumors express transcriptional signatures that correlate with their metastatic propensity. A number of these signatures have been deployed in the clinic as risk stratification tools. However, the molecular basis of these clinically useful prognostic signatures has remained a largely unresolved area of controversy. We recently found that many prognostic signatures reflect the activity of the MYC oncogene, which in turn regulates tumor metastasis through specific effects on cancer cell invasion and migration. These findings offer a general framework for understanding the molecular basis of clinically prognostic transcriptional signatures and suggest potentially new avenues for studying metastasis. Cancer Res; 71(6); 2034–7. ©2011 AACR.

Accumulating evidence has pointed to an intriguing model of tumor progression whereby some primary tumors are molecularly preconfigured to metastasize relatively early (rather than later) in their evolution (1). Several clinical and experimental observations support this idea: (i) many cancer patients have metastatic tumors without obvious primaries; (ii) circulating tumor cells or actual micrometastases can be found in patients with very early-stage tumors; and (iii) aggressive primary tumors express transcriptional profiles that correlate with propensity to eventual metastasis or are differentially expressed by metastatic lesions compared with more indolent tumors (1–3). Moreover, there is clear selection for oncogenic mutations that promote cancer cell proliferation and survival during tumor evolution, but the selective advantage of purely metastasis-promoting mutations remains unclear. This thinking has led to the interesting hypothesis that a primary tumor’s metastatic propensity may be dictated in large measure by molecular changes that occur early in tumorigenesis (and are reflected by the expression of prognostic signatures), rather than solely by metastasis-enabling mutations per se, which are thought to arise in rare metastatic precursors later in tumor progression (1, 4).

Over the past decade, independent groups have reported the identification of many different “poor prognosis” gene expression signatures, mainly in breast cancer, which were derived through transcriptional profiling in both human tumors and experimental systems (5). Curiously, these different signatures are independently prognostic in the same tumor data sets but overlap minimally with respect to component genes. Additionally, many signature genes relate to cell proliferation, which raises the speculation that gene expression profiles might be useful biomarkers for risk stratification in cancer patients but only indirectly relate to the molecular mechanisms that specifically regulate cancer cell metastasis. Against this backdrop, we recently found that 13 different “poor outcome” gene expression signatures are coordinately regulated by the MYC oncogene in breast cancer cells. In addition, MYC is specifically necessary for the invasion and metastasis of these cells in experimental xenografts independent of its effects on proliferation and survival (5). These results suggest a model whereby early-stage primary tumors that express poor-prognosis transcriptional signatures have high MYC activity that directly contributes to their metastatic spread.

The MYC transcription factor is one of the most important somatically mutated oncogenes in human cancer. Recent studies suggest that inherited polymorphisms on 8q24 (near the MYC locus), which powerfully modify solid tumor predisposition, also influence MYC transcript expression (6). Somatic amplification and overexpression of MYC is seen in both high-grade premalignancy and invasive tumors and is associated with poor outcome in different human tumor types (7–12). Furthermore, many transforming oncogenes ultimately drive MYC expression either directly or indirectly, thus assuring that deregulation of the MYC pathway is one of the most common features of human tumorigenesis. The MYC oncoprotein can confer a selective advantage on cancer cells by promoting proliferation, cell survival, differentiation blockade, genetic instability, and angiogenesis, all of which may indirectly contribute to metastasis (Fig. 1; refs. 13–15). Cell proliferation, survival, and genetic instability promoted by MYC presumably result in more cancer cells with unstable genomes and, therefore, a higher likelihood of further mutation contributing to progression.

Aside from these indirect functions, however, it is becoming increasingly clear that MYC may also directly control cellular invasion and migration and, thus, metastasis, by regulating the...
expresses specific downstream programs. For example, MYC can regulate the epithelial-to-mesenchymal transition (EMT) that is necessary for cellular invasion and migration in some contexts. MYC does this by promoting TGFβ-mediated activation of the SNAIL transcription factor, both directly and indirectly through a microRNA network involving a LIN28B/let-7/HMGA2 cascade (Fig. 1; refs. 16–22). Importantly, however, we found that RNA interference (RNAi)-mediated MYC knockdown in highly metastatic MDA-MB-231 breast cancer cells disrupts cellular invasion, migration, and metastasis in vivo, independent of effects on EMT. This suggests that MYC may also regulate metastasis-promoting mechanisms beyond EMT (5). Consistent with this idea, MYC can regulate cell-cell–matrix interactions through transcriptional activation of LGALS1, which is a β-galactosidase–binding protein that promotes cell migration and invasion (23). Similarly, OPN is a MYC-regulated integrin-binding ligand that has been widely implicated in stimulating cancer cell migration and invasion (24, 25). MYC also cooperates with SKP2 to recruit MIZ1 and p300 into a transcriptional complex that activates RhoA, which is necessary for migration, invasion, and lung metastasis in vivo (26). In addition, MYC repression of ID2 inhibits expression of the secreted protein SEMA3F, which has been found to increase cell migration and invasion through RhoA activation and modulation of the actin cytoskeleton (Fig. 1; refs. 27–29). Clearly, more work is needed to comprehensively understand all MYC transcriptional targets that can directly contribute to metastasis.

Although MYC is necessary for the invasive and metastatic behavior of cancer cells, it seems to be insufficient (5, 26). Furthermore, MYC promotes but, paradoxically, can also retard migration depending on cell type (30). These and other
observations suggest that MYC likely cooperates with other genes (particularly RAS pathway components) to promote both the early (e.g., invasion and migration) and late (e.g., seeding) phases of metastatic progression (15, 31–33). Systematic and unbiased approaches should increasingly reveal the spectrum of cellular and molecular contexts in which MYC promotes distant metastasis. Furthermore, MYC-driven primary tumors seem to remain dependent on this oncogene even after becoming established (34). If MYC-driven metastatic tumors also remain dependent (currently, an unanswered question), then strategies to target MYC in cancer patients with advanced disease may prove to be clinically useful.

Beyond direct transcriptional regulation of metastasis-relevant target genes, MYC may also play a more global role in regulating the metastatic phenotype. MYC is a powerful cellular reprogramming factor that determines normal and cancer cell differentiation (35). Presumably, cancer cells in an undifferentiated, more stem cell–like state more easily migrate to and seed distant sites. Along these lines, MYC regulates the expression of different stem cell–associated transcriptional profiles (5, 33). How MYC regulates cellular differentiation is still not completely clear. However, genome-wide chromatin immunoprecipitation (ChIP) profiling studies have recently shown that MYC binds widely across the human genome (36). Other recent studies also suggest that MYC-directed transcriptional complexes containing histone-modifying enzymes may, in part, promote cellular reprogramming by uniquely inducing genome-wide changes in chromatin conformation (36–39). These findings suggest a fascinating but still speculative model. Perhaps MYC contributes to metastasis by globally altering the epigenomic landscape of cancer cells, thus providing a permissive molecular context in which additional, cooperative molecular alterations can specifically promote different aspects of the metastatic phenotype. If this speculative model proves to be correct, a deeper understanding of MYC complexes that promote metastasis in this way may provide new opportunities to target this important but currently “undruggable” cancer pathway. Further work will be required to fully explore this model.

Disclosure of Potential Conflicts of Interest

S. Ramaswamy is a recipient of a commercial research grant by Astra Zeneca.

Acknowledgments

We apologize to the many, many MYC investigators whose work we were unable to fully cite in this minireview owing to space restrictions.

Received October 15, 2010; revised December 7, 2010; accepted December 13, 2010; published online March 15, 2011.

References


MYC and Metastasis
Anita Wolfer and Sridhar Ramaswamy


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/71/6/2034

Cited articles
This article cites 39 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/6/2034.full#ref-list-1

Citing articles
This article has been cited by 11 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/71/6/2034.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.